Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas

J. Cortes-Prieto, A. Lledo, C. Avila, L. Cortes-Garcia, A. D'Acunto, M. Luisi, A. M. Comaru-Schally, Andrew V Schally

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Reversible temporary medical oophorectomy using long-acting agonist analogs of LH-RH was tried in three infertile patients suffering from large endometriomas of the ovary. These patients had stage IV disease according to the revised 1985 classification of the American Fertility Society. D-Ala6-des-Gly10-LH-RH propylamide (D-Ala6-LH-RH PA), in a dose of 125 μg, was administered intramuscularly every 48 hours to one patient, and daily to the other two patients, for 22, 17, and 14 weeks, respectively. Two patients subsequently received 100 μg of D-Trp-LH-RH for 4 weeks in order to compare its efficacy with D-Ala6-LH-RH PA. Clinical controls, pelvic ultrasonography, and routine laboratory tests and hormone assays were done periodically. Ultrasonography images showed a reduction in the size of endometriomas after the second or third week of treatment. This reduction was maintained throughout and continued after the period of treatment. Suppression of the pituitary and estrogen responses was obtained rapidly, but some transient increments were occasionally found. Progesterone levels always decreased and remained in the range of the early follicular phase. Most intervals of uterine bleeding were prolonged. An evident improvement of abdominal pain, dysmenorrhea, and dyspareunia was found. Administration of D-Trp6-LH-RH was more effective than D-Ala6-LH-RH PA in most of the parameters tested. After discontinuation of treatment, all three patients had a prolonged follicular phase with a normal luteal phase during the first cycle. One woman became pregnant in the fourth cycle after discontinuation of D-Ala6-LH-RH PA and delivered a normal baby. A second patient, in whom the symptoms recurred, required additional treatment. After the discontinuation of analogs, the third patient remained asymptomatic and maintained reduction of ovarian size for more than 1 year. In view of improvement, verified clinically and by pelvic ultrasonography, and the rapid recovery of the ovalutory function, prolonged administration of superactive analogs of LH-RH should be considered for the treatment of endometriosis.

Original languageEnglish
Pages (from-to)290-297
Number of pages8
JournalInternational Journal of Fertility
Volume32
Issue number4
StatePublished - Dec 1 1987
Externally publishedYes

Fingerprint

Endometriosis
Gonadotropin-Releasing Hormone
Ultrasonography
Follicular Phase
Therapeutics
Dyspareunia
Dysmenorrhea
Uterine Hemorrhage
Luteal Phase
Recovery of Function
Ovariectomy
Abdominal Pain
Progesterone
Fertility
Pregnant Women
Ovary
Estrogens
Hormones

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Cortes-Prieto, J., Lledo, A., Avila, C., Cortes-Garcia, L., D'Acunto, A., Luisi, M., ... Schally, A. V. (1987). Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas. International Journal of Fertility, 32(4), 290-297.

Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas. / Cortes-Prieto, J.; Lledo, A.; Avila, C.; Cortes-Garcia, L.; D'Acunto, A.; Luisi, M.; Comaru-Schally, A. M.; Schally, Andrew V.

In: International Journal of Fertility, Vol. 32, No. 4, 01.12.1987, p. 290-297.

Research output: Contribution to journalArticle

Cortes-Prieto, J, Lledo, A, Avila, C, Cortes-Garcia, L, D'Acunto, A, Luisi, M, Comaru-Schally, AM & Schally, AV 1987, 'Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas', International Journal of Fertility, vol. 32, no. 4, pp. 290-297.
Cortes-Prieto J, Lledo A, Avila C, Cortes-Garcia L, D'Acunto A, Luisi M et al. Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas. International Journal of Fertility. 1987 Dec 1;32(4):290-297.
Cortes-Prieto, J. ; Lledo, A. ; Avila, C. ; Cortes-Garcia, L. ; D'Acunto, A. ; Luisi, M. ; Comaru-Schally, A. M. ; Schally, Andrew V. / Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas. In: International Journal of Fertility. 1987 ; Vol. 32, No. 4. pp. 290-297.
@article{e667a3952abf4000a57e15ae69aa3115,
title = "Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas",
abstract = "Reversible temporary medical oophorectomy using long-acting agonist analogs of LH-RH was tried in three infertile patients suffering from large endometriomas of the ovary. These patients had stage IV disease according to the revised 1985 classification of the American Fertility Society. D-Ala6-des-Gly10-LH-RH propylamide (D-Ala6-LH-RH PA), in a dose of 125 μg, was administered intramuscularly every 48 hours to one patient, and daily to the other two patients, for 22, 17, and 14 weeks, respectively. Two patients subsequently received 100 μg of D-Trp-LH-RH for 4 weeks in order to compare its efficacy with D-Ala6-LH-RH PA. Clinical controls, pelvic ultrasonography, and routine laboratory tests and hormone assays were done periodically. Ultrasonography images showed a reduction in the size of endometriomas after the second or third week of treatment. This reduction was maintained throughout and continued after the period of treatment. Suppression of the pituitary and estrogen responses was obtained rapidly, but some transient increments were occasionally found. Progesterone levels always decreased and remained in the range of the early follicular phase. Most intervals of uterine bleeding were prolonged. An evident improvement of abdominal pain, dysmenorrhea, and dyspareunia was found. Administration of D-Trp6-LH-RH was more effective than D-Ala6-LH-RH PA in most of the parameters tested. After discontinuation of treatment, all three patients had a prolonged follicular phase with a normal luteal phase during the first cycle. One woman became pregnant in the fourth cycle after discontinuation of D-Ala6-LH-RH PA and delivered a normal baby. A second patient, in whom the symptoms recurred, required additional treatment. After the discontinuation of analogs, the third patient remained asymptomatic and maintained reduction of ovarian size for more than 1 year. In view of improvement, verified clinically and by pelvic ultrasonography, and the rapid recovery of the ovalutory function, prolonged administration of superactive analogs of LH-RH should be considered for the treatment of endometriosis.",
author = "J. Cortes-Prieto and A. Lledo and C. Avila and L. Cortes-Garcia and A. D'Acunto and M. Luisi and Comaru-Schally, {A. M.} and Schally, {Andrew V}",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "32",
pages = "290--297",
journal = "International Journal of Fertility",
issn = "0020-725X",
publisher = "MSP International",
number = "4",

}

TY - JOUR

T1 - Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas

AU - Cortes-Prieto, J.

AU - Lledo, A.

AU - Avila, C.

AU - Cortes-Garcia, L.

AU - D'Acunto, A.

AU - Luisi, M.

AU - Comaru-Schally, A. M.

AU - Schally, Andrew V

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Reversible temporary medical oophorectomy using long-acting agonist analogs of LH-RH was tried in three infertile patients suffering from large endometriomas of the ovary. These patients had stage IV disease according to the revised 1985 classification of the American Fertility Society. D-Ala6-des-Gly10-LH-RH propylamide (D-Ala6-LH-RH PA), in a dose of 125 μg, was administered intramuscularly every 48 hours to one patient, and daily to the other two patients, for 22, 17, and 14 weeks, respectively. Two patients subsequently received 100 μg of D-Trp-LH-RH for 4 weeks in order to compare its efficacy with D-Ala6-LH-RH PA. Clinical controls, pelvic ultrasonography, and routine laboratory tests and hormone assays were done periodically. Ultrasonography images showed a reduction in the size of endometriomas after the second or third week of treatment. This reduction was maintained throughout and continued after the period of treatment. Suppression of the pituitary and estrogen responses was obtained rapidly, but some transient increments were occasionally found. Progesterone levels always decreased and remained in the range of the early follicular phase. Most intervals of uterine bleeding were prolonged. An evident improvement of abdominal pain, dysmenorrhea, and dyspareunia was found. Administration of D-Trp6-LH-RH was more effective than D-Ala6-LH-RH PA in most of the parameters tested. After discontinuation of treatment, all three patients had a prolonged follicular phase with a normal luteal phase during the first cycle. One woman became pregnant in the fourth cycle after discontinuation of D-Ala6-LH-RH PA and delivered a normal baby. A second patient, in whom the symptoms recurred, required additional treatment. After the discontinuation of analogs, the third patient remained asymptomatic and maintained reduction of ovarian size for more than 1 year. In view of improvement, verified clinically and by pelvic ultrasonography, and the rapid recovery of the ovalutory function, prolonged administration of superactive analogs of LH-RH should be considered for the treatment of endometriosis.

AB - Reversible temporary medical oophorectomy using long-acting agonist analogs of LH-RH was tried in three infertile patients suffering from large endometriomas of the ovary. These patients had stage IV disease according to the revised 1985 classification of the American Fertility Society. D-Ala6-des-Gly10-LH-RH propylamide (D-Ala6-LH-RH PA), in a dose of 125 μg, was administered intramuscularly every 48 hours to one patient, and daily to the other two patients, for 22, 17, and 14 weeks, respectively. Two patients subsequently received 100 μg of D-Trp-LH-RH for 4 weeks in order to compare its efficacy with D-Ala6-LH-RH PA. Clinical controls, pelvic ultrasonography, and routine laboratory tests and hormone assays were done periodically. Ultrasonography images showed a reduction in the size of endometriomas after the second or third week of treatment. This reduction was maintained throughout and continued after the period of treatment. Suppression of the pituitary and estrogen responses was obtained rapidly, but some transient increments were occasionally found. Progesterone levels always decreased and remained in the range of the early follicular phase. Most intervals of uterine bleeding were prolonged. An evident improvement of abdominal pain, dysmenorrhea, and dyspareunia was found. Administration of D-Trp6-LH-RH was more effective than D-Ala6-LH-RH PA in most of the parameters tested. After discontinuation of treatment, all three patients had a prolonged follicular phase with a normal luteal phase during the first cycle. One woman became pregnant in the fourth cycle after discontinuation of D-Ala6-LH-RH PA and delivered a normal baby. A second patient, in whom the symptoms recurred, required additional treatment. After the discontinuation of analogs, the third patient remained asymptomatic and maintained reduction of ovarian size for more than 1 year. In view of improvement, verified clinically and by pelvic ultrasonography, and the rapid recovery of the ovalutory function, prolonged administration of superactive analogs of LH-RH should be considered for the treatment of endometriosis.

UR - http://www.scopus.com/inward/record.url?scp=0023600074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023600074&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 290

EP - 297

JO - International Journal of Fertility

JF - International Journal of Fertility

SN - 0020-725X

IS - 4

ER -